Bloomberg Law, January 13, 2022: Minority groups could have a harder time accessing Aduhelm, Biogen Inc.’s Alzheimer’s drug, under Medicare’s preliminary decision to limit coverage to patients enrolled in clinical trials, policy analysts say. But we explain that it will ensure that patients understand that the drug is experimental, with proven risks but no proven benefits.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
Breast Augmentation and Plastic Surgery Are on the Rise – What Are the Risks?
Honeysuckle Magazine, December 29, 2021: There has been a 33 percent increase in cosmetic surgery for women between 2000 and 2020. However, the measures meant to guarantee their safety are disputed among experts such as the National Center for Health Research.
Read More »Pfizer Covid Pill’s Fast Signoff Spurs Row Over Skipped Step
Bloomberg Law, December 22, 2021: The FDA authorized Pfizer Inc.’s pill to treat Covid-19 without first getting input from an expert advisory panel. We explain why that could further undermine trust in an agency already facing scrutiny over its rapid decision-making during the pandemic.
Read More »Califf heads to Capitol Hill for FDA confirmation hearing
Politico: FDA Commissioner nominee Dr. Robert Califf makes his case for the job before the Senate health panel. We ask: What will he do about accelerated approval of ineffective medical treatments?
Read More »Equal Access to Merck Covid Pill Imperiled by Prescribing Rules
Bloomberg Law, December 2, 2021: Merck’s antiviral drug molnupiravir—if authorized by the agency—would offer for the first time in the U.S. an at-home treatment option for patients with mild to moderate Covid-19 who are at risk of severe disease.
Read More »